Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neurosense Therapeutics Ltd. ( (NRSN) ) has provided an announcement.
On March 16, 2026, NeuroSense Therapeutics reported that results from its PARADIGM Phase 2b clinical trial of PrimeC in people living with ALS were published in JAMA Neurology, underscoring the therapy’s strong safety profile over 18 months and clinically meaningful outcomes, such as slower functional decline and improved bulbar function. The multinational trial also showed a 64% relative reduction in ALS‑related complications for early PrimeC treatment and biomarker changes consistent with disease‑modifying activity, findings that reinforce the drug’s scientific rationale and underpin NeuroSense’s plans to advance PrimeC into a larger confirmatory Phase 3 program, potentially strengthening the company’s position in the competitive ALS treatment landscape.
Conducted across leading ALS centers in Italy, Canada, and Israel, PARADIGM enrolled 68 participants in a randomized, double‑blind, placebo‑controlled design followed by a 12‑month open‑label extension, during which early PrimeC recipients maintained a 7.92‑point ALSFRS‑R functional advantage at 18 months. The JAMA Neurology publication, co‑authored by prominent international ALS experts, validates PrimeC’s multi‑pathway mechanism through iron‑regulatory and microRNA biomarker modulation and marks a key milestone for NeuroSense as it transitions toward late‑stage development and seeks to translate these mid‑stage data into regulatory and clinical momentum in ALS.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical‑stage biotechnology company focused on developing disease‑modifying therapies for neurodegenerative conditions, with a primary emphasis on amyotrophic lateral sclerosis (ALS). Its lead product candidate, PrimeC, is an investigational fixed‑dose oral combination that targets multiple biological pathways involved in ALS progression, including neuroinflammation, iron dysregulation, and microRNA imbalance.
Average Trading Volume: 218,552
Technical Sentiment Signal: Sell
Current Market Cap: $25.52M
See more insights into NRSN stock on TipRanks’ Stock Analysis page.